Introduction {#Sec1}
============

The eNTPDases are a family of enzymes that hydrolyze extracellular nucleoside 5′ di- and triphosphates in the presence of divalent cations \[[@CR1]\]. There are integral membrane protein NTPDases, embedded in both the cell surface membrane and internal membranes, as well as NTPDases that can be secreted extracellularly as soluble nucleotidases \[[@CR2]--[@CR7]\]. Four of the eight human NTPDases described to date (NTPDase1--3, 8) are integral membrane, cell-surface glycoproteins, with large extracellular domains and two transmembrane domains located near the N- and C-termini \[[@CR1], [@CR8]\].

Several areas of sequence conservation in the NTPDases have been noted. Besides the four apyrase conserved regions (ACRs) originally described \[[@CR9]\], and ACR5 described later \[[@CR10], [@CR11]\], there are also two other conserved protein motifs in the NTPDases that have been named ACR1a and ACR4a \[[@CR12]\]. No amino acid residues in the ACR1a region have thus far been assigned any functional significance. However, ACR4a was found to include a conserved glycine residue (glycine 263 in NTPDase3 \[[@CR12]\]) whose mutation to alanine caused complete inactivation of the enzyme, presumably by large-scale disruption of native tertiary and quaternary structures of the nucleotidase \[[@CR12]\]. A similar, but slightly less pronounced effect was found by mutation of another conserved glycine residue to alanine in NTPDase3, i.e., glycine 462, located in ACR5 \[[@CR12]\].

The enzymatic activities, and therefore presumably the physiological functions, of the cell-surface NTPDases are dependent on their oligomeric state (quaternary structure). Conditions that stabilize NTPDase homo-oligomers increase activity, while conditions that destabilize NTPDase oligomers decrease nucleotidase activities \[[@CR13]\]. For example, solubilization with Triton X-100 detergent disrupts the native oligomeric structure and dramatically decreases nucleotidase activities for both NTPDase1 (CD39 \[[@CR14]\]) and NTPDase3 \[[@CR15]\]. Lectins such as the tetravalent Con A protein can induce lattices of specific glycoproteins, even in the presence of complex mixtures of glycoproteins exposed to Con A \[[@CR16]\]. Thus, several studies have reported that Con A increases NTPDase activity \[[@CR17]--[@CR19]\], presumably by stabilization of the quaternary structure. At least in NTPDase3, this Con A effect seems to be mediated via the conserved N81 glycosylation site, located near ACR1 \[[@CR20]\]. It has also been shown that chemical cross-linking can stabilize quaternary structure, and therefore the lysine specific cross-linking agent, DSS, has been used to assess possible changes in quaternary structure as a consequence of site-directed mutagenesis of NTPDase3 \[[@CR12], [@CR21]--[@CR24]\]. Of course, the enzymatic activities of the NTPDases are also dependent on their tertiary structures. Cibacron blue (Reactive Blue 2) is a triazine dye that has affinity for the nucleotide binding site of many proteins, and has been shown to inhibit nucleotide handling enzymes in general \[[@CR25], [@CR26]\], as well as specific NTPDases \[[@CR27], [@CR28]\]. Cibacron blue binding to NTPDase3 is retained after solubilization and monomerization with Triton X-100 \[[@CR12]\]. As a consequence, this dye has been used as a measure of native tertiary structure for NTPDase3, since it does not bind to heat-denatured NTPDase3 or to certain mutants that appear to have disrupted tertiary structures \[[@CR29]\].

While screening chemical modification reagents for effects on NTPDase3 nucleotidase activities, we made the unusual and unexpected observation that reaction of wild-type NTPDase3 with the tyrosine selective reagent, *N*-acetylimidazole, increases enzyme activity. Previously, treatment with aspirin (acetylsalicylic acid) was shown to inhibit rat platelet NTPDase \[[@CR30]\], possibly via acetylation. In the present study, it seems unlikely that an increase in NTPDase3 activity would be induced by acetylation of an active site residue by *N*-acetylimidazole. Therefore, we mutated several conserved tyrosine residues in the vicinity of the glycine residue that was previously proposed to be important for NTPDase3 higher-order structure (glycine 263 in ACR4a \[[@CR12]\]). These tyrosine residues are also located near the computer-predicted helix-loop-helix dimerization domain in the primary structure of NTPDase3 (^238^NTSDIMQVS^246^ \[[@CR31]\]).

We found that substitution of tyrosine at position 252 abolished the increase in activity caused by *N*-acetylimidazole, suggesting that modification of this tyrosine residue is responsible for the increased activity of the wild-type enzyme. Monomerization of the wild-type enzyme by solubilization with the detergent Triton X-100 eliminated the increase in activity upon treatment with *N*-acetylimidazole. However, no gross changes in the tertiary or quaternary structures were detected by Cibacron blue binding, DSS cross-linking, or native gel electrophoresis. Nevertheless, changes in response to lectin and cross-linking induced increases in nucleotidase activities were evident in the mutants non-responsive to *N*-acetylimidazole. Therefore, we speculate that Tyr 252, as well as the amino acid residues nearby Tyr 252 in ACR4a, may be important for full enzymatic activity of NTPDase3 due to their subtle influence on native tertiary and/or quaternary structure.

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

The QuikChang™ site-directed mutagenesis kit was purchased from Stratagene. Oligonucleotides were synthesized by the DNA Core Facility at the University of Cincinnati. Lipofectamine Plus Reagent, Dulbecco's modified Eagle medium (DMEM), calf serum, and antibiotics/antimycotics were obtained from Gibco/Life Technologies. The mammalian expression vector pcDNA3 was obtained from Invitrogen. The chemical cross-linking reagent disuccinimidyl suberate (DSS) and the SuperSignal chemiluminescence reagents were purchased from Pierce Chemical Company. Cibacron Blue Gel (Affi-Gel Blue), pre-cast SDS-PAGE 4%--15% gradient mini-gels, and goat anti-rabbit horseradish peroxidase conjugated secondary antibody were obtained from Bio-Rad Laboratories. *N*-Acetylimidazole (*N*-AI), Ampicillin, nucleotides, and other reagents were from Sigma.

Site-directed mutagenesis of NTPDase3 {#Sec4}
-------------------------------------

Mutagenesis of NTPDase3 in pcDNA3 vector was performed using the Quick Change site-directed mutagenesis kit (Stratagene) as described previously \[[@CR12], [@CR15], [@CR23], [@CR24], [@CR29], [@CR32]\]. The sense nucleotides used for mutagenesis are as follows: Y252A, 5′-CTGTATGGCTACGTA[GCA]{.ul}ACGCTCTACACACAC-3′;Y255A, 5′-TACGTATACACGCTC[GCA]{.ul}ACACACAGCTTCCAG-3′;Y262A, 5′-CACAGCTTCCAGTGC[GCA]{.ul}GGCCGGAATGAGGCT-′3;Y252F, 5′-TATGGCTACGTA[TTC]{.ul}ACGCTCTACACA-3′;Y255F, 5′-GTATACACGCTC[TTC]{.ul}ACACACAGCTTC-3′;Y262F, 5′-AGCTTCCAGTGC[TTT]{.ul}GGCCGGAATGAG-′3;

Altered codons are underlined, but the complementary antisense oligonucleotides also necessary for mutagenesis are not shown. The presence of the desired mutation and lack of undesired mutations were confirmed by DNA sequencing. The mutated NTPDase3 cDNA was used to transform competent cells as described by the manufacturer (Stratagene).

Transient transfection {#Sec5}
----------------------

COS-1 cells were grown and transfected with wild-type and mutant NTPDase3 cDNA, as previously described \[[@CR12], [@CR15], [@CR23], [@CR24], [@CR29], [@CR32]\]. An empty pcDNA3 vector was transfected into COS cells and used as a background control for nucleotidase assays. Cells were harvested 48 h post-transfection and crude total membrane preparations were obtained as described \[[@CR12], [@CR15], [@CR23], [@CR24], [@CR29], [@CR32]\].

Protein assay {#Sec6}
-------------

Protein concentrations were determined using the Bio-Rad Coomassie blue dye binding assay, using bovine serum albumin as the standard, with the modifications of Stoscheck \[[@CR33]\].

Nucleotidase assays {#Sec7}
-------------------

Nucleotidase activities were determined by measuring the concentration of inorganic phosphate (P~i~) released from the ATP or ADP substrates in the presence of Mg^2+^ or Ca^2+^. Assays were performed at 37 °C as previously described \[[@CR12], [@CR15], [@CR23]\], modified from Fiske and Subbarow \[[@CR34]\]. Nucleotidase activities were corrected for COS-1/pcDNA3 background (provided by the empty pcDNA3 vector transfected into COS-1 cells) and for differences in expression levels relative to those of wild-type, as determined by Western blotting.

Western blot analysis {#Sec8}
---------------------

For Western blot, proteins were resolved in a 4%--15% linear gradient SDS-PAGE gradient gel (BioRad 4--15%) and transferred to a polyvinylidene fluoride (PVDF) membrane. Blots were probed with an anti-C-terminal peptide NTPDase3 antibody, as previously described \[[@CR32]\].

Chemical cross-linking {#Sec9}
----------------------

COS cell membrane preparations (at a total protein concentration of 0.1 mg/ml) were diluted in 20 mM MOPS, 5 mM MgCl~2~ buffer, pH 7.4, and incubated for 20 min at 22 °C with 200 µM disuccinimido suberate (DSS) freshly dissolved in DMSO. Non-cross-linked samples were treated with the same volume of DMSO, and the final DMSO concentration of all samples was less than 2% of the total sample volume. The cross-linking reaction was stopped by incubation with an excess (10 mM) of lysine for 5 min at 22 °C. Samples were then either analyzed for intermolecular cross-linking by reducing SDS-PAGE and Western blot analysis, or assayed for Mg^2+^-ATPase activity as described above.

Analysis of Cibacron blue binding {#Sec10}
---------------------------------

Cibacron blue binding assays have been described previously \[[@CR12], [@CR23], [@CR29]\].

Native gel electrophoresis of wild-type and mutant NTPDases {#Sec11}
-----------------------------------------------------------

NTPDase3 membrane preparations were solubilized for 10 min at room temperature in digitonin (1% final concentration), a detergent known to preserve the native quaternary structure and the activity of the NTPDases \[[@CR13], [@CR14]\]. Soluble proteins were isolated by centrifugation and run on 6% Laemmli native gel containing 0.1% digitonin as described previously \[[@CR12]\].

Treatment of wild-type and mutant NTPDase3 with Concanavalin A {#Sec12}
--------------------------------------------------------------

Concanavalin A (Con A) was prepared at a concentration of 5 mg/ml in 20 mM MOPS buffer containing 100 mM NaCl, 1 mM MnCl~2~ and 1 mM CaCl~2~, pH 7.4. Wild-type and tyrosine mutant NTPDase3 total membrane preparations (2 µg) were incubated with 5 µl of 5.0 mg/ml Con A at 37 °C for 15 min before the addition of substrate. Nucleotidase assays were performed in the presence of 5 mM Ca^2+^ or Mg^2+^, at a final nucleotide concentration of 2.5 mM.

N-acetylimidazole treatment {#Sec13}
---------------------------

Membrane preparations were diluted to a total protein concentration of 0.1 mg/ml in pH 7.4 MOPS buffer containing 5 mM MgCl~2~. At 0 time (before addition of *N*-acetylimidazole) 20-µl aliquots were diluted into 260 µl of an ice-cold stop solution containing an excess of lysine (14.5 mM) to quench the reaction, 100 mM KCl, 5 mM MgCl~2~, 1 mM EGTA and 20 mM TrisYHCl, pH 7.0. *N*-Acetylimidazole (2 mM) was then added to the remainder of each membrane preparation at 22 °C. At 5, 10, 20, 30, 45 and 60 min, 20 µl aliquots were diluted with 260 µl of stop solution as described above. At 61 min, hydroxylamine was added to a final concentration of 200 mM to the remainder of the *N*-acetylimidazole-treated membrane preparation to quench the reaction and reverse the acetylation of tyrosine residues. At 62, 65, 75, 90 and 120 min, 21-µl aliquots were diluted with 259 µl stop solution as before. Mg^2+^-ATPase and Mg^2+^-ADPase assays were performed for all time points.

Time dependence of Mg-ATPase activity {#Sec14}
-------------------------------------

Kinetics of Mg^2+^-dependent ATPase hydrolysis before and after treatment with *N*-acetylimidazole or the lysine-specific cross linker, DSS, were measured in a Beckman DU-800 spectrophotometer, using a NADH-linked-enzyme spectrophotometric assay \[[@CR35]\], as described previously for NTPDase2 \[[@CR22]\] and NTPDase3 \[[@CR20]\]. The NADH-linked-enzyme assay was used to allow the continuous monitoring of ATPase activity as a function of time. After pre-incubation to bring the cuvettes and samples to 37 °C, the reactions were initiated by addition of a small volume of NTPDase3 enzyme.

Solubilization and nucleotidase assays {#Sec15}
--------------------------------------

Cell membranes (at a total protein concentration of 0.1 mg/ml) were solubilized in 1% Triton X-100, 5 mM MgCl~2~ and 20 mM MOPS buffer pH 7.4 at 22 °C for 10 min with occasional mixing, followed by centrifugation at 150,000 *g* for 30 min at 22 °C. Mg^2+^ and Ca^2+^ ATPase and ADPase activities were measured in presence of 0.1% Triton X-100, after adding nucleotide to a final nucleotide concentration of 0.435 mM, using a malachite green phosphate assay \[[@CR36]\] to measure nucleotidase activities, since Triton X-100 causes turbidity in the modified Fiske and Subbarow assay \[[@CR34]\].

Results {#Sec16}
=======

Rationale for selection and analysis of tyrosine mutants {#Sec17}
--------------------------------------------------------

We mutated several tyrosine residues (Tyr 252, 255, and 262) in the vicinity of a computer predicted, myc-type, helix-loop-helix dimerization domain (^238^NTSDIMQVS \[[@CR31]\]), which is also nearby a region of the enzyme (ACR4a) previously identified as containing a glycine residue important for folding or structure of NTPDase3 (Gly 263 \[[@CR12]\], see Table [1](#Tab1){ref-type="table"}). Tyrosines corresponding to residues 252 and 255 in NTPDase3 are conserved in all NTPDases, while the tyrosine analogous to tyrosine 262 in NTPDase3 is conserved in the cell-surface membrane NTPDases (NTPDase1, 2, and 3), but not in the other NTPDases (see Table [1](#Tab1){ref-type="table"}). Besides the sequence conservation and the location of the tyrosine residues, another reason for analyzing these mutations was suggested by the unusual experimental observation that *N*-acetylimidazole, a tyrosine selective chemical modification reagent, caused an increase in enzymatic activity of wild-type NTPDase3 (Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). We hypothesized that modification of one or more of these tyrosine residues might be responsible for the increased enzyme activity. Figure 1*N*-acetylimidazole increases NTPDase3 Mg^2+^-ATPase and Mg^2+^-ADPase activities of wild-type and Y262A mutants, but not Y252A or Y255A mutants. Mutants \[Y252A (po), Y255A (□), and Y262A (▵)\] and wild-type NTPDase3 (•) COS cell membrane preparations were incubated with *N*-acetylimidazole for various times, and the reaction was terminated by dilution into stop solution as described in Materials and methods. Nucleotidase assays were performed in the presence of 5 mM Mg^2+^, at a final nucleotide concentration of 2.5 mM. Top panel: ATPase activities. Bottom panel: ADPase activities. Hydroxylamine was added to a final concentration of 200 mM at 61 min, to reverse tyrosine modification. All activities are expressed as a percentage of the nucleotidase activities before N-acetylimidazole was added.Figure 2*N*-acetylimidazole increases NTPDase3 Mg^2+^-ATPase and Mg^2+^-ADPase activities of wild-type, Y255F and Y262F mutants, but not the Y252F mutant. Mutants \[Y252F (po), Y255F (□), and Y262F (▵)\] and wild-type NTPDase3 (•) COS cell membrane preparations were incubated with *N*-acetylimidazole for various times, and the reaction was terminated by dilution into stop solution as described in Materials and methods. Nucleotidase assays were performed in presence of 5 mM Mg^2+^, at a final nucleotide concentration of 2.5 mM. Top panel: ATPase activities. Bottom panel: ADPase activities. Hydroxylamine was added to a final concentration of 200 mM at 61 min, to reverse tyrosine modification. All activities are expressed as a percentage of the nucleotidase activities before *N*-acetylimidazole was added.Table 1Multiple sequence alignments of extended NTPDase ACR4a regionseNTPDaseSpeciesAccession no.Amino acid sequenceNTPDase3HumanAF034840250 YV**[Y]{.ul}**TL**[Y]{.ul}**THSFQC**[Y]{.ul}***[G]{.ul}*RNEARatNP_835207250 YV**[Y]{.ul}**TL**[Y]{.ul}**THSFQC**[Y]{.ul}***[G]{.ul}*RNEAMouseAY376710250 YV**[Y]{.ul}**TL**[Y]{.ul}**THSFQC**[Y]{.ul}***[G]{.ul}*RNEANTPDase2HumanQ9Y5L3231 QH**[Y]{.ul}**RV**[Y]{.ul}**THSFLC**[Y]{.ul}***[G]{.ul}*RDQVRatO35795231 QH**[Y]{.ul}**RV**[Y]{.ul}**THSFLC**[Y]{.ul}***[G]{.ul}*RDQIChickenP79784228 QP**[Y]{.ul}**KV**[Y]{.ul}**THSFLC**[Y]{.ul}***[G]{.ul}*RDQVNTPDase1HumanP49961244 KD**[Y]{.ul}**NV**[Y]{.ul}**THSFLC**[Y]{.ul}***[G]{.ul}*KDQAMouseP55772243 ED**[Y]{.ul}**TV**[Y]{.ul}**THSFLC**[Y]{.ul}***[G]{.ul}*KDQAPigQ9MYU4244 KN**[Y]{.ul}**SV**[Y]{.ul}**THSFLC**[Y]{.ul}***[G]{.ul}*KDQANTPDase8MouseAY3644442237 AN**[Y]{.ul}**SV**[Y]{.ul}**THSYLCF*[G]{.ul}*RDQINTPDase4HumanAF016032309 HV**[Y]{.ul}**RV**[Y]{.ul}**VATFLGF*[G]{.ul}*GNAANTPDase7HumanAF269255309 HV**[Y]{.ul}**RV**[Y]{.ul}**VTTFLGF*[G]{.ul}*GNFANTPDase5HumanAF039918233 ST**[Y]{.ul}**KL**[Y]{.ul}**THSYLGF*[G]{.ul}*KAAANTPDase6HumanAF039916285 RT**[Y]{.ul}**KL**[Y]{.ul}**SYSYLGL*[G]{.ul}*LMSAThe sequence alignment shows the region near apyrase conserved region 4a (ACR4a). The three tyrosine residues mutated in this work (human NTPDase3 Y252, Y255, and Y262) are in bold and underlined in the aligned ACR4a sequences. The conserved glycine residue in ACR4a previously shown to be important for the structure of NTPDase3 (G263, \[[@CR12]\]) is italicized and double-underlined. Although only a few representative sequences of the NTPDases are shown in the table, it should be noted that residues corresponding to tyr252 and tyr255 in NTPDase3 are conserved in all NTPDase sequences determined to date.

Protein expression levels {#Sec18}
-------------------------

Expression levels of the NTPDase3 mutants were calculated by quantification of Western blots as previously described \[[@CR12]\] and compared to wild-type NTPDase3 using an Alpha Innotech FluorChem 8800 Imager. The values presented are the average of three separate transfections (Table [2](#Tab2){ref-type="table"}), and the specific activities for ATP and ADP of the NTPDase3 mutants were corrected for variations in expression levels relative to those of the wild-type (see Table [2](#Tab2){ref-type="table"}). Table 2Nucleotidase activities of wild-type (WT) and mutant NTPDase3 enzymesNTPDase3 enzyme% Wt. level of expressionNormalized Mg^2+^-ATPase activity (% wt.)Normalized Ca^2+^-ATPase activity (% wt.)Normalized Mg^2+^-ADPase activity (% wt.)Normalized Ca^2+^-ADPase activity (% wt.)Wild-type100144 ± 10 (100)413 ± 35 (100)57 ± 5 (100)83 ± 15 (100)Y252F60 ± 5138 ± 10 (95)360 ± 30 (87)48 ± 5 (84)84 ± 8(101)Y255F85 ±7170 ± 12 (118)397 ± 24 (96)97 ± 12 (170)96 ± 10(115)Y262F84 ± 5158 ± 9 (109)394 ± 23 (95)59 ± 8 (103)84 ± 18 (101)Y252A52 ± 6140 ± 12 (97)345 ± 36 (83)51 ±7 (89)86 ± 7 (103)Y255A67 ± 5172 ± 15 (119)392 ± 26 (95)104 ± 15 (182)106 ± 10 (127)Y262A70 ± 4159 ± 7(110)410 ± 25 (99)60 ± 12 (105)85 ± 20(102)Values given represent the means ± standard deviations of three separate transfections (which were matched to their own wild-type and empty pcDNA3 vector controls). Activities were measured in presence of 5 mM MgCl~2~ or CaCl~2~ at a final concentration of 2.5 mM ATP or ADP. Values were normalized for different NTPDase3 protein expression levels by dividing the nucleotidase activity (expressed in the table as mmol Pi/mg protein/h) by the expression level relative to the wild-type enzyme.

Nucleotidase activities of NTPDase3 mutants {#Sec19}
-------------------------------------------

ATPase and ADPase nucleotidase activities of all mutants were determined in the presence of either Mg^2+^ or Ca^2+^ (Table [2](#Tab2){ref-type="table"}). All tyrosine mutants were active and displayed nucleotidase activities similar to the wild-type NTPDase3, with expression levels 52%--85% of the wild-type NTPDase3 (Table [2](#Tab2){ref-type="table"}). One difference noted is the increased Mg^2+^-ADPase activity of the Y255A (182%) and Y255F (170%) mutants, relative to the wild-type.

N-acetylimidazole increases Mg^2+^-ATPase/ADPase activity {#Sec20}
---------------------------------------------------------

*N*-acetylimidazole increases both ATPase and ADPase activity of wild-type NTPDase3 in presence of Mg^2+^. After 60 min of reaction, Mg^2+^-ATPase and Mg^2+^-ADPase activities are increased by approximately 1.9-fold (Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, upper panels) and 1.35-fold (Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, lower panels), respectively. A substantial portion of the increase in activity is rapidly reversible by hydroxylamine added at 61 min (Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}), suggesting that tyrosine modification, rather than lysine modification, is responsible for the effect, since tyrosine modification, unlike lysine modification by *N*-AI, is reversible by hydroxylamine. As is evident from Figure [2](#Fig2){ref-type="fig"}, *N*-acetylimidazole is unable to increase the nucleotidase activity of the Y252F mutant, in contrast to the wild-type, Y255F, and Y262F mutant NTPDase3. Interestingly, the *N*-acetylimidazole-induced increase is also greatly attenuated in the Y255A mutant, as well as being eliminated in the Y252A mutant (Figure [1](#Fig1){ref-type="fig"}).

Kinetics of Mg-ATPase activity after N-acetylimidazole treatment {#Sec21}
----------------------------------------------------------------

To investigate the reaction kinetics of Mg^2+^-ATPase after *N*-acetylimidazole-mediated chemical modification of wild-type NTPDase3, continuous measurement of the Mg-ATPase activity was made using the linked enzyme assay. The data obtained was fit using a double exponential decay function (Figure [3](#Fig3){ref-type="fig"}), suggesting two processes causing decreases in enzymatic activity at 37 °C, which occur on different time scales. *N*-Acetylimidazole decreases the rate of decay of activity, resulting in the measured increase in activity (Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Figure 3Time dependence of NTPDase3 Mg^2+^-ATPase activity with and without *N*-acetylimidazole treatment. Wild-type COS cell membrane preparations were treated with water or *N*-acetylimidazole for 60 min and the reaction was terminated by dilution in stop solution as described in Materials and methods. The Mg^2+^-ATPase activity of 3 µg protein was measured by the NADH-linked enzyme assay \[[@CR35]\].

Is N-acetylimidazole modification associated with higher oligomer formation? {#Sec22}
----------------------------------------------------------------------------

To investigate whether the *N*-acetylimidazole modification triggers higher oligomer formation, wild-type NTPDase3 was treated with *N*-acetylimidazole for various times (0, 5, 30, 45 and 60 min) and then run on a native gel. All samples ran with same electrophoretic mobility as untreated NTPDase3, indicating that *N*-acetylimidazole does not initiate higher order oligomer formation as measured by this technique. In addition, the electrophoretic mobilities of wild-type NTPDase3 and the tyrosine mutants are indistinguishable in this native gel electrophoresis, suggesting that the mutants have the same gross oligomeric structure as wild-type NTPDase3. Also, a lysine-specific cross-linking agent, disuccinimido suberate (DSS), was used to assess gross changes in quaternary structure. After reducing SDS-PAGE and Western blotting, wild-type and all NTPDase3 mutants made in this study were similarly cross-linked into dimers, suggesting that the gross quaternary structures of the mutants are similar to those of the wild-type (all data mentioned above is not shown due to lack of demonstrable differences between the wild-type and mutant enzymes).

Analysis of tertiary structure of the mutants by Cibacron blue binding {#Sec23}
----------------------------------------------------------------------

To explore the possibility of global misfolding induced by point mutations leading to the inability to bind the nucleotide analogue triazine dye, Cibacron blue, Cibacron blue binding assays were performed as previously described \[[@CR12]\]. Misfolded mutants are unable to bind Cibacron blue affinity matrix, as is denatured NTPDase3 (exemplified by the boiled, wild-type enzyme \[[@CR12]\]). All the mutants described in this study bound to the Cibacron blue matrix like the wild-type enzyme (data not shown), suggesting that there are no gross changes in tertiary conformations of the mutants affecting the ability to bind the nucleotide analogue, Cibacron blue.

Effect of N-acetylimidazole on Triton X-100 solubilized wild-type NTPDase Mg-ATPase activity {#Sec24}
--------------------------------------------------------------------------------------------

To investigate whether *N*-acetylimidazole can increase Mg^2+^-ATPase activity of wild-type NTPDase3 after dissociation into monomers by Triton X-100, wild-type NTPDase3 was solubilized with Triton X-100 either prior to, or after, treatment with *N*-acetylimidazole. The results given in Table [3](#Tab3){ref-type="table"} indicate that *N*-acetylimidazole cannot increase the Mg^2+^-ATPase activity of Triton X-100 solubilized (monomeric) NTPDase3, and that after *N*-AI is used to increase the activity of the membrane-bound wild-type NTPDase3, that increase in activity is abolished by subsequent Triton X-100 solubilization. Therefore, it appears that the increase in enzyme activity seen upon *N*-acetylimidazole treatment may be dependent on native quaternary structure, or upon the native tertiary structure, since the native tertiary structure may be modified by disruption of the quaternary structure by Triton X-100. Table 3Effect of Triton X-100 solubilization of *N*-acetylimidazole stimulation of wild-type NTPDase3 Mg^2+^-ATPase activityTreatmentMg^2+^-ATPase activity (µmol/mg/h)% Control activityNone (control)103 ± 4(100%)*N*-acetylimidazole229 ± 10220%*N*-acetylimidazole,7.0 ± 1.56.8%then Triton X-100Triton X-1005.6 ± 0.65.4%Triton X-100,5.6 ± 0.65.4%then *N*-acetylimidazole

Effect of Concanavalin A on NTPDase3 wild-type and tyrosine mutants {#Sec25}
-------------------------------------------------------------------

Concanavalin A is a tetravalent protein that binds to glycans and can stabilize the oligomeric structure of glycoproteins by induction of the formation of protein oligomeric lattices \[[@CR16]\]. Concanavalin A was previously shown to increase the nucleotidase activity of several membrane bound, oligomeric NTPDases \[[@CR18], [@CR22], [@CR37], [@CR38]\]. The elimination of a single glycosylation site located near ACR1 (N81 in NTPDase3) was shown to greatly diminish the ability of Con A to increase the nucleotidase activity of NTPDase3 \[[@CR20]\]. Thus, we used Con A as another probe to determine if the *N*-AI effect may be related to a quaternary structure effect. The data in Figure [4](#Fig4){ref-type="fig"} are consistent with the *N*-acetylimidazole data in Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, i.e., the mutants which do not respond to *N*-AI also respond less to the stimulating effect of Con A, suggesting some subtle conformational changes in the Y252F, Y252A, and Y255A mutants, which may subtly affect the quaternary structure. Figure 4Effect of Concanavalin A pre-treatment on Mg^2+^-ATPase activities of wild-type and tyrosine mutant NTPDase3. Wild-type and mutant COS cell membranes were pre-incubated with Con A for 15 min at 37 °C prior to addition of ATP to start the reactions as described in Materials and methods. Data shown are the means T standard deviations for each NTPDase3 sample.

Effect of DSS chemical cross-linking on the nucleotidase activity of tyrosine mutant and wild-type NTPDase3 {#Sec26}
-----------------------------------------------------------------------------------------------------------

The lysine specific chemical modification reagent, DSS, was used to treat wild-type and mutant NTPDases to observe the effects on Mg-ATPase activities. As can be seen in the top panel of Figure [5](#Fig5){ref-type="fig"}, DSS treatment increased the activity of the wild-type as well as the Y255F and Y262F mutants, but decreased the activity of the Y252F mutant, whose activity is also not stimulated by *N*-acetylimidazole (see Figure [2](#Fig2){ref-type="fig"}). In addition, the correlation between stimulation of activity by *N*-AI and by DSS cross-linking also exists for the tyrosine to alanine mutants, since both Y252A and Y255A, which are not stimulated by *N*-AI (see Figure [1](#Fig1){ref-type="fig"}), are also not stimulated by DSS cross-linking (bottom panel of Figure [5](#Fig5){ref-type="fig"}). Figure 5Effect of DSS chemical cross-linking on Mg^2+^-ATPase activities of wild-type and tyrosine mutant NTPDase3. Wild-type and mutant COS cell membranes were cross-linked with 200 µM DSS for 10 min at 22 °C as described in Materials and methods, the reactions stopped by quenching with excess lysine, and the nucleotidase activities measured. White bars are without DSS cross-linking (controls), while gray bars are NTPDase3 samples after DSS cross-linking. Data shown are the means ± standard deviations for each NTPDase3 sample.

Discussion {#Sec27}
==========

In this study we used site-directed mutagenesis to mutate several conserved tyrosines to investigate which tyrosine residue(s) is(are) responsible for mediating the increase in Mg^2+^-ATPase activity caused by acetylation with the chemical modification reagent, *N*-acetylimidazole (Table [1](#Tab1){ref-type="table"}). These tyrosine residues (see Table [1](#Tab1){ref-type="table"}) are in the vicinity of the glycine residue that was previously proposed to be important for NTPDase3 higher-order structure (due to results obtained upon mutation of glycine 263 in ACR4a \[[@CR12]\]), and are also located near the computer-predicted helix-loop-helix dimerization domain \[[@CR31]\] of NTPDase3 (^238^NTSDIMQVS^246^). These amino acids were first changed to alanine to compare results to our previous studies where NTPDase3 residues were typically mutated to alanine \[[@CR12], [@CR23], [@CR24], [@CR29], [@CR32]\]. However, for the purpose of introducing the least structural perturbations and yet allowing us to delineate the residue(s) modified by *N*-acetylimidazole, these tyrosine residues were also mutated to phenylalanine. As can be seen in Table [2](#Tab2){ref-type="table"}, mutation of none of these three tyrosine residues to either alanine or phenylalanine inactivated the enzyme, indicating that they are not an essential part of the catalytic site.

Upon treatment with *N*-acetylimidazole, wild-type NTPDase3 displays a time-dependent increase in Mg^2+^-ATPase and Mg^2+^-ADPase activities (see Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). A substantial portion of the increase in activity is rapidly reversible by hydroxylamine treatment, suggesting that tyrosine modification, rather than lysine modification, is responsible for the effect. The Y252F mutant does not exhibit this *N*-acetylimidazole-induced increase in activity, while the nearby Y255F and Y262F mutants behave like the wild-type enzyme (Figure [2](#Fig2){ref-type="fig"}). This suggests that modification (acetylation by *N*-acetylimidazole) of tyrosine at position 252 mediates the effect. However, it is not clear why the increase in activity is not completely reversible with hydroxylamine treatment, if the effect is solely mediated by a single tyrosine acetylation, as the mutagenesis results suggest. Consistent with the phenylalanine mutants, the Y252A mutant is unresponsive to *N*-AI treatment. However, the Y255A mutant, unlike the Y255F mutant, is also largely unresponsive to *N*-AI treatment (Figure [1](#Fig1){ref-type="fig"}). The reason for this is not known, but we speculate that the Y255A mutation, being less conservative in nature and introducing a substantially smaller side chain at that position than the Y255F mutation, could cause a perturbation in the folding in that area of the protein, resulting in a microenvironment at Y252 that is either less conducive for the reaction of Y252 with *N*-AI, or alternatively, less conducive to the change in local conformation that presumably occurs after acetylation of Y252 by *N*-AI.

There are no obvious, global changes in tertiary or quaternary structures in any of the mutants described in this study, since all the mutants have expression levels and enzyme activities not very different from the wild-type enzyme (Table [2](#Tab2){ref-type="table"}). In addition, they all behave like wild-type NTPDase3 in Cibacron blue binding assays, as well as on native gels, and have similar relative susceptibility to intermolecular DSS cross-linking (data not shown since all characteristics were not different from the wild-type).

However, we found that Triton X-100 solubilization abolished the *N*-acetylimidazole-mediated increase in Mg^2+^-ATPase activity of wild-type NTPDase3, and that monomerization by Triton X-100 solubilization subsequent to stimulation of activity by *N*-AI negates the N-AI-induced increase in activity (Table [3](#Tab3){ref-type="table"}). This is important since solubilization with Triton X-100 detergent has been shown to cause a decrease in enzyme activity accompanying disruption of the native oligomeric structure to monomeric enzyme for both NTPDase1 (CD39 \[[@CR14]\]) and NTPDase3 \[[@CR15]\]. This suggests that the *N*-acetylimidazole-mediated increase in enzyme activity might be associated with a subtle effect on the quaternary structure, which is not detected by the global nature of the DSS cross-linking and native gel analyses. Consistent with this is the fact that the *N*-acetylimidazole induced increase of the ATPase activity is more pronounced than the increase of the ADPase activity (see Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}), since, based on Triton X-100 solubilization (monomerization) experiments, it appears that ATPase activity is more dependent on native quaternary structure than ADPase activity for both NTPDase1 \[[@CR14]\] and NTPDase3 \[[@CR15]\]. Also consistent with the possibility that the N-acetylimidazole-mediated increase in enzyme activity might be associated with a subtle effect on the quaternary structure is the observation that *N*-AI does not increase the activity (data not shown) of bacterially expressed NTPDase6 \[[@CR39]\], which is a soluble, monomeric NTPDase that contains the conserved tyrosines corresponding to residues 252 and 255 in NTPDase3 (see Table [1](#Tab1){ref-type="table"}). In addition, there is precedence for *N*-acetylimidazole acetylation of proteins affecting quaternary structure and stability of oligomeric proteins, since Pal et al. reported that this reagent acetylated surface exposed tyrosine residues, resulting in a destabilization of the native subunit assembly of the alpha-crystallin protein \[[@CR40]\]. Alternatively, monomerization by Triton X-100 may also modify the native tertiary structure of NTPDase3, and it could be that this alteration in the tertiary structure leads to the observed abolition of the *N*-acetylimidazole-mediated increase in Mg-ATPase activity.

Concanavalin A, a tetravalent ligand known to stabilize the oligomeric structure of glycoproteins by induction of high-order protein oligomer lattice formation \[[@CR16]\], increases the nucleotidase activity of several eNTPDases \[[@CR18], [@CR19], [@CR37], [@CR38], [@CR41]--[@CR43]\]. This Con A effect has been previously attributed to stabilization of the native quaternary structure \[[@CR13], [@CR20]\]. Thus, we used this lectin as an additional probe of subtle conformational effects of the mutations in this study. The results obtained (see Figure [4](#Fig4){ref-type="fig"}) are consistent with, and complementary to, the *N*-AI results in Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. Thus, mutations in this region that affect the ability of *N*-AI acetylation to increase NTPDase3 enzyme activity, possibly via subtle stabilization of the native quaternary structure, also manifest themselves with regard to the ability of Con A to stimulate enzyme activity. As a result, Con A has a lesser effect on the activity of the Y252F mutant than on the Y255F, Y262F, and wild-type NTPDase3 (Figure [4](#Fig4){ref-type="fig"}, top panel).

Chemical cross-linking using the lysine-specific agent, DSS, is also consistent with the *N*-AI and Con A results, since the tyrosine mutants that are unable to respond to NAI also do not respond like the wild-type NTPDase3 to DSS cross-linking with a similar increase in activity (Figure [5](#Fig5){ref-type="fig"}). Instead of the increase in activity of the wild-type enzyme, these mutants display reduced activities after lysine-specific cross-linking (DSS treatment). This reduction in activity could be due to reaction at other lysine residues, the negative effect of which is masked in the wild-type enzyme by the larger positive effect on activity after reaction with a different set of lysine residues.

Very recently, Grinthal and Guidotti \[[@CR44]\] found that for the related CD39/NTPDase1 protein, the CD39 dimer appears to be in relatively rapid equilibrium with monomeric CD39. Thus, those authors proposed that NTPDase1 exists in a relatively unstable dimeric quaternary structure, which allows exchange of monomer protein partners between different dimers. Since the dimer form of oligomeric NTPDases has higher nucleotidase activity than the monomer form, it follows that any mutation or chemical modification that shifts this monomer-dimer equilibrium more towards the dimer would be expected to increase enzyme activity. Thus, one possible explanation for the *N*-acetylimidazole induced increase in NTPDase3 activity observed in our studies is that acetylation of tyrosine 252 causes a relatively small increase in the stability of the dimer (i.e., slightly shifts the monomer-dimer equilibrium more in favor of the dimer), which is observed as an increase in activity, but is not detected by the relatively crude chemical cross-linking and native gel analyses utilized in this study.
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ACR

:   apyrase conserved region

BSA

:   bovine serum albumin

Con A

:   Concanavalin A

DMEM

:   (Dubelco's modified Eagle medium)

DMSO

:   dimethyl sulfoxide

DSS

:   disuccinimido suberate

DTT

:   (dithiothreitol)

MOPS

:   (3-\[*N*-morpholino\] propanesulfonic acid

*N*-AI

:   *N*-acetylimidazole

NTPDases

:   (nucleoside triphosphate diphosphohydrolases)

Pi

:   (inorganic phosphate)

PVDF

:   polyvinylidene fluoride

TBS

:   (tris buffered saline)
